Group sales (+1% to €11,941m) saw good volume growth (+5%), which was more or less eaten up by lower prices (-2%) and adverse FX effects (-3%). Gross profit strongly increased from 53.9% to 57.4% driven by higher Pharmaceuticals’ sales and lower raw material prices and EBITDA jumped +23% to €3,3376m befitting from all segments. Earnings attributable to shareholders rose +13% to €1,511m. Operating CF was highly affected by the obligations to be fulfilled in connection with
26 Apr 2016
Pharmaceuticals showed strong growth
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Pharmaceuticals showed strong growth
Bayer AG (BAYN:WBO) | 0 0 0.5% | Mkt Cap: 80,975m
- Published:
26 Apr 2016 -
Author:
Martin Schnee -
Pages:
3
Group sales (+1% to €11,941m) saw good volume growth (+5%), which was more or less eaten up by lower prices (-2%) and adverse FX effects (-3%). Gross profit strongly increased from 53.9% to 57.4% driven by higher Pharmaceuticals’ sales and lower raw material prices and EBITDA jumped +23% to €3,3376m befitting from all segments. Earnings attributable to shareholders rose +13% to €1,511m. Operating CF was highly affected by the obligations to be fulfilled in connection with